NASDAQ: ABCLAbcellera Biologics Inc Stock Ownership - Who owns Abcellera Biologics?
Insider buying vs selling
Have Abcellera Biologics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Andrew Booth | Chief Financial Officer | 2026-06-03 | 250,000 | $0.19 | $47.50kBuy |
| John S. Montalbano | Director | 2026-05-14 | 20,000 | $4.77 | $95.40kBuy |
| Andrew Booth | Chief Financial Officer | 2026-02-27 | 42,600 | $3.42 | $145.69kBuy |
| Thermopylae Holdings Ltd | 10% Owner | 2026-02-27 | 38,000 | $3.44 | $130.72kBuy |
| Thermopylae Holdings Ltd | 10% Owner | 2026-02-26 | 177,457 | $3.27 | $580.28kBuy |
| John S. Montalbano | Director | 2025-11-26 | 50,000 | $3.57 | $178.45kBuy |
ABCL insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ABCL insiders and whales buy or sell their stock.
ABCL Shareholders
What type of owners hold Abcellera Biologics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Carl L. G. Hansen | 18.66% | 56,984,009 | $325.38M | Insider |
| Thermopylae Holdings Ltd | 18.38% | 56,134,097 | $320.53M | Insider |
| Baker Bros Advisors LP | 9.91% | 30,275,938 | $172.88M | Institution |
| John Hamer | 4.83% | 14,734,623 | $84.13M | Insider |
| Capital World Investors | 4.38% | 13,361,096 | $76.29M | Institution |
| Two Sigma Investments LP | 3.46% | 10,562,065 | $60.31M | Institution |
| Td Waterhouse Canada Inc | 3.13% | 9,564,659 | $54.61M | Institution |
| Ubs Am A Distinct Business Unit Of Ubs Asset Management Americas LLC | 2.48% | 7,575,476 | $43.26M | Institution |
| Ubs Group Ag | 1.38% | 4,209,052 | $24.03M | Institution |
| Arrowmark Colorado Holdings LLC | 1.34% | 4,105,095 | $23.44M | Institution |
ABCL vs Biotech Stocks
Abcellera Biologics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.